Enhancing Diagnostic Accuracy for Lung Cancer through Combined Detection of Multiple Tumor Markers

Objective To explore the application value of combined detection of multiple tumor markers in diagnosing lung cancer (LC). Methods A total of 32 small cell lung cancer (SCLC) patients and 107 non-small cell lung cancer (NSCLC) patients, including 68 lung adenocarcinoma (LADC) patients and 39 lung squamous cell carcinoma (LSCC) patients diagnosed in our hospital from January 2019 to December 2021, were enrolled. 102 benign lung disease (BCD) patients (including pneumonia, pulmonary tuberculosis, and chronic obstructive pulmonary disease) were chosen as the control group. Serum tumor markers were detected in all patients, and their positive rates and concentrations were compared. Receiver operating characteristic (ROC) curve analysis was used to calculate the diagnostic performance of individual and combined tests. Results The positive rate and concentration of carcinoembryonic antigen (CEA) were upregulated in the LADC group (P Conclusions CYFRA21-1 combined with CEA assists in diagnosing LADC, CYFRA21-1 combined with SCCAg assists in diagnosing LSCC, and CA153 assists in diagnosing SCLC. These four serum tumor markers can be used to aid in diagnosing LC and differentiating its pathological types.